fingolimod norameda
norameda, uab - fingolimodas - kietosios kapsulės - 0,5 mg - fingolimod
chantico
g.l. pharma gmbh - fingolimodas - kietosios kapsulės - 0,5 mg - fingolimod
fingolimod teva
teva gmbh - fingolimodas - kietosios kapsulės - 0,5 mg - fingolimod
fingolimod zentiva
zentiva k.s. - fingolimodas - kietosios kapsulės - 0,5 mg - fingolimod
fingolimod medochemie
medochemie ltd. - fingolimodas - kietosios kapsulės - 0,5 mg - fingolimod
fingolimod grindeks
as grindeks - fingolimodas - kietosios kapsulės - 0,5 mg - fingolimod
efigalo
krka, d.d., novo mesto - fingolimodas - kietosios kapsulės - 0,5 mg - fingolimod
ponvory
janssen-cilag international n.v. - ponesimod - išsėtinė sklerozė, grįžtamoji-pervedimo - imunosupresantai - ponvory is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features.
fingolimod mylan
mylan ireland limited - fingolimod hidrochloridas - išsėtinė sklerozė, grįžtamoji-pervedimo - imunosupresantai - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older:patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 ir 5. 1)orpatients su sparčiai besivystančiomis sunkus grįžtamoji pervedimo išsėtinės sklerozės apibrėžta 2 ar daugiau išjungus atkryčių po metų, ir su 1 ar daugiau gadolinio didinti pakitimų smegenų mrt arba gerokai padidinti t2 pralaimėjimai apkrovos, palyginti su ankstesniais neseniai mrt.
fingolimod mylan
mylan ireland limited - fingolimod hidrochloridas - išsėtinė sklerozė, grįžtamoji-pervedimo - imunosupresantai - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 ir 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.